RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating
📰 Original Source
Read full article at Finance →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.